Work

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Year: 2017
Type: review
Abstract: // Xiaohui Wang 1,2,* , Zhengqiang Bao 1,2,* , Xiaoju Zhang 3,* , Fei Li 1 , Tianwen Lai 1 , Chao Cao 1 , Zhihua Chen 1 , Wen Li 1 , Huahao Shen 1,4 and Songmin Ying 1,2 1 Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital, Institute of Respiratory Diseases, Zhejiang University School of Medicine, Hangzhou, China 2 Department of Pharmacology, Zhejiang University School of Medicine, Hangzhou, China 3 Department of Respiratory Medicine, Zhengzhou University People’s Hospital, Henan Provincial People’s Hospital, Zhengzhou, China 4 State Key Laboratory of Respiratory Diseases, Guangzhou, China * These authors have contributed equally to this manuscript Correspondence to: Songmin Ying, email: // Huahao Shen, email: // Keywords : PD-1, PD-L1, nivolumab, pembrolizumab, cancer Received : August 12, 2016 Accepted : March 01, 2017 Published : May 31, 2017 Abstract Background: PD-1/PD-L1 inhibitors have been implicated as potentially effective anti-cancer therapies. Some clinical randomized controlled trials (RCTs) have been completed for a variety of PD-1/PD-L1 inhibitors to treat various malignancies, and more RCTs are still under way. We carried out this systematic meta-analysis to evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors. Methods: We searched PubMed, EMBASE, clinical trial registers, conference reports, and related reviews. Eligible RCTs that compared PD-1/PD-L1 inhibitors with other chemotherapy agents or placebo in solid tumor patients were included. For each RCT, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), stable disease rate (SDR), progressive disease rate (PDR), and adverse events (AEs) were pooled for meta-analysis. Findings: Based on an analysis of 10 eligible RCTs, PD-1/PD-L1 inhibitors were found to significantly improve PFS (Hazard ratio (HR), 0.65; 95% confidence interval (CI) 0.53 to 0.79, P <0.001), OS (HR, 0.69; 95%CI 0.62 to 0.76, P <0.001), and ORR (Risk Ratio (RR) 2 . 92; 95% confidence interval (CI) 2.06 to 4.15, P <0.00001) in all populations, including melanoma and NSCLC subgroups. However, they failed to increase the DCR of cancer patients (RR 1.15; 95%CI 0.91 to 1.45, P =0.25). Furthermore, less AEs were observed in the PD-1/PD-L1 inhibitor groups than the control groups. Interpretation: PD-1 inhibitors are more effective for improving the PFS, OS, and ORR of cancer patients with little toxicity, despite having little effect on increasing of the DCR.
Source: Oncotarget
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W2619738298
FWCI: 1.378
Cites: 40
Cited by: 81
Related to: 9